InvestSMART

Patrys Limited (ASX:PAB)

ALERT: Price-sensitive ASX Announcement for PAB
Current share price for PAB : $0.038 0.008 (26.67%)+
Announcement
Release
28 Jan 2026 9:36AM
Price at Release
$0.030
Full Release
download
Summary
Patrys Limited has completed the acquisition of Reliis Pty Ltd, making it a wholly-owned subsidiary. Reliis, a clinical-stage pharmaceutical company, brings its injectable quetiapine program, RLS-2201, into Patrys’ pipeline, aiming to address acute-care needs. Following this acquisition, Patrys has appointed Leanne Kite and Dino Cercarelli as Non-Executive Directors to strengthen its board. The company will issue Consideration Securities as part of the acquisition terms. The RLS-2201 program aims to leverage the known safety profile of quetiapine to address delirium in healthcare settings. This strategic move aligns with Patrys' growth objectives in clinical-stage therapies.
Key Points
  • Completion of Reliis Pty Ltd acquisition by Patrys Limited.
  • Reliis becomes a wholly-owned subsidiary of Patrys.
  • RLS-2201 injectable quetiapine program added to Patrys’ pipeline.
  • Appointment of Leanne Kite and Dino Cercarelli as Non-Executive Directors.
  • Issuance of Consideration Securities as per acquisition agreement.
  • RLS-2201 targets delirium management in acute-care settings.
  • The acquisition aligns with Patrys’ strategy to expand its clinical-stage pipeline.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.